Technical Analysis for ATHA - Athira Pharma, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 2.49 | -4.96% | -0.13 |
ATHA closed down 4.96 percent on Monday, March 18, 2024, on 69 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Mar 21
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 200 DMA | Bearish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Support | Bullish | -4.96% | |
Calm After Storm | Range Contraction | -4.96% | |
Lower Bollinger Band Walk | Weakness | -4.96% | |
Wide Bands | Range Expansion | -4.96% | |
Oversold Stochastic | Weakness | -4.96% | |
Boomer Sell Setup | Bearish Swing Setup | -3.11% | |
200 DMA Support | Bullish | -3.11% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 18 hours ago |
Down 3% | about 18 hours ago |
Fell Below 200 DMA | about 18 hours ago |
Fell Below Previous Day's Low | about 18 hours ago |
Possible NR7 | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/21/2024
Athira, headquartered in Seattle, is a drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule therapeutic, in later-stage clinical trials for Alzheimer’s.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drug Development Nasdaq 100 Index Innovative Therapies Brain Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drug Development Nasdaq 100 Index Innovative Therapies Brain Disorders
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.2984 |
52 Week Low | 1.33 |
Average Volume | 400,936 |
200-Day Moving Average | 2.55 |
50-Day Moving Average | 3.28 |
20-Day Moving Average | 3.53 |
10-Day Moving Average | 3.13 |
Average True Range | 0.30 |
RSI (14) | 33.33 |
ADX | 41.23 |
+DI | 16.68 |
-DI | 29.19 |
Chandelier Exit (Long, 3 ATRs) | 3.40 |
Chandelier Exit (Short, 3 ATRs) | 3.32 |
Upper Bollinger Bands | 4.75 |
Lower Bollinger Band | 2.31 |
Percent B (%b) | 0.07 |
BandWidth | 69.10 |
MACD Line | -0.21 |
MACD Signal Line | -0.02 |
MACD Histogram | -0.1885 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.82 | ||||
Resistance 3 (R3) | 2.85 | 2.77 | 2.77 | ||
Resistance 2 (R2) | 2.77 | 2.69 | 2.76 | 2.75 | |
Resistance 1 (R1) | 2.63 | 2.63 | 2.59 | 2.60 | 2.73 |
Pivot Point | 2.55 | 2.55 | 2.53 | 2.54 | 2.55 |
Support 1 (S1) | 2.41 | 2.47 | 2.37 | 2.38 | 2.25 |
Support 2 (S2) | 2.33 | 2.41 | 2.32 | 2.23 | |
Support 3 (S3) | 2.19 | 2.33 | 2.22 | ||
Support 4 (S4) | 2.16 |